Q/C Technologies (QCLS) Q3 2025 earnings summary

Executive summary

• Shifted strategic focus from pharmaceutical R&D to energy-efficient blockchain and quantum-class laser-based computing, leveraging an exclusive license with LightSolver Ltd. for laser processing units (LPUs).

• Initiated prototype development of qc-LPU100, targeting AI, DePin Token, and cryptocurrency infrastructure markets.

• Evaluating divestiture of legacy pharmaceutical assets to fund new technology initiatives.

Financial highlights

• Net loss of $2.8 million for Q3 2025, compared to $1.9 million in Q3 2024; net loss of $5.7 million for the nine months ended September 30, 2025, versus $21.3 million in the prior year period.

• No revenue generated from product sales in Q3 or year-to-date 2025.

• Cash on hand was $6.9 million and marketable securities $3.1 million as of September 30, 2025.

• Working capital of $4.6 million and stockholders' equity of $14.3 million at quarter-end.

• Operating cash outflows of $5.9 million for the nine months ended September 30, 2025.

Outlook and guidance

• Management believes current financial resources are sufficient to fund operations and contractual obligations for the next twelve months.

• Plans to finalize qc-LPU100 prototypes, conduct pilot testing, and pursue strategic partnerships and additional financing.

• Anticipates initial revenue from LPU sales and leasing by late 2026.